Terumo (TRUMY) Set to Post Quarterly Earnings on Thursday

Terumo (OTCMKTS:TRUMY) is expected to announce its results after the market closes on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.0085) per share and revenue of $1.94 billion for the quarter.

Terumo (OTCMKTS:TRUMY) last released its earnings results on Friday, August 7th. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.17 by $0.13. Terumo had a net margin of 13.83% and a return on equity of 10.44%. The business had revenue of $1.97 billion during the quarter, compared to analysts’ expectations of $1.84 billion. On average, analysts expect Terumo to post $0.86 EPS for the current fiscal year and $0.80 EPS for the next fiscal year.

Terumo Stock Up 0.2%

TRUMY opened at $15.07 on Thursday. Terumo has a twelve month low of $12.08 and a twelve month high of $16.99. The company has a quick ratio of 1.37, a current ratio of 2.19 and a debt-to-equity ratio of 0.13. The company has a 50-day moving average price of $14.82 and a 200 day moving average price of $14.02. The company has a market cap of $22.24 billion, a PE ratio of 21.23 and a beta of 0.82.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Nomura upgraded Terumo from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 30th. Zacks Research upgraded Terumo from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 13th. Two research analysts have rated the stock with a Strong Buy rating. Based on data from MarketBeat, the stock presently has an average rating of “Strong Buy”.

Terumo Company Profile

Terumo Corporation is a Japan-based medical technology company that develops, manufactures and sells medical devices and healthcare products. Its offerings support hospitals, physicians and other healthcare providers across areas including cardiovascular care, interventional procedures, blood management, cell and gene therapies, and general medical care.

The company’s products include catheters, guidewires, stents and other devices used in cardiovascular and endovascular procedures, as well as blood bags, apheresis systems, cell-processing technologies, infusion and injection products, and hospital equipment.